ClinicalTrials.gg
RecruitingNCT06678698Updated Nov 8, 2024

Acute Effect of Photobiomodulation in Individuals with Hypertension

An interventional study of Panel Effective Photobiomodulation Therapy and Sham Panel Photobiomodulation Therapy in Hypertension, sponsored by Universidade Federal de Sao Carlos. Recruiting at 1 site in Brazil. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Universidade Federal de Sao Carlos · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled May 2024, registered Oct 2024).
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
128th of 189
48 · median 80
Started
2024
with 11 others
No phase
112 of 209
15 open now
Primary completion
2025-01
later than 1 of 32 live
Registered
185th of 209
by date

Among the 209 studies in Hypertension with a site in Brazil, this one is the 128th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 112 with no phase, reaches primary completion later than 1 of the 32 other live ones, and was the 185th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

This is a randomized, double-blind and sham-controlled clinical trial that aims to evaluate and compare the acute effect of full-body photobiomodulation (PBM) and modified ILIB (Intravascular laser irradiation of blood) on blood pressure, endothelial function and arterial stiffness in individuals with hypertension. Participants (n=48) will be equally, randomly and secretly allocated into one of 4 groups: Panel Group; Panel Sham Group; Modified ILIB group; and Modified ILIB Sham Group. Participants aged 40 to 60 years old, diagnosed with hypertension and using control drugs for at least 3 months will be included. Participants will be assessed at pre- and post-intervention for: BP; endothelial function; arterial stiffness; blood nitrite; and thermography. In the post-intervention period, the ambulatory blood pressure monitoring will also be carried out. Participants will receive a single application of PBM, which, depending on the group, may be full-body irradiation from an LED panel (660 nm; 25.34 J/cm²; 42.24 mW/cm²), modified ILIB (660 nm; 42,462 J/cm²; 35.385 W/cm²), or the respective sham therapies. Data homogeneity and normality will be verified by the Levene and Shapiro-Wilk tests, which will determine the choice of subsequent tests. A statistical significance of 5% will be considered.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • photobiomodulation
  • low-level light therapy
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sedentary or irregularly inactive individuals (IPAQ)
  • Both sexes
  • Age between 40 to 60 years old
  • Clinical diagnosis of hypertension for at least 3 months with difficulty in blood pressure control
  • Hypertension classification up to stage 2
  • Individuals who have a prescription for hypertension control drugs and have been using these drugs for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Diabetes diagnosis
  • Smokers
  • > 30 kg/m²
  • Cardiac pacemaker use
  • Presence of arrhythmias or other decompensated cardiovascular diseases
  • Musculoskeletal, orthopedic or neurological conditions that make it unable to participate in the procedures
  • Presence of cognitive deficits that make it difficult to understand the assessments
  • Presence of active neoplasia, under suspicion or after 5 years in remission period
  • Presence of tattoos (covering a large body area, or the anterior wrist region)
  • Photosensitive drugs use
  • Pregnant women or under suspicion
  • Presence of epilepsy or seizures
  • Participants who present a systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg on the day of the intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Panel Group

    Participants who will receive full-body photobiomodulation irradiation, from a panel of LEDs

    Device: Panel Effective Photobiomodulation Therapy

  • Sham comparator
    Panel Sham Group

    Participants who will receive full-body photobiomodulation irradiation, with the device turned-off

    Device: Sham Panel Photobiomodulation Therapy

  • Experimental
    Modified ILIB Group

    Participants who will receive photobiomodulation irradiation with the transcutaneous ILIB method

    Device: Modified ILIB Photobiomodulation Therapy

  • Sham comparator
    Modified ILIB Sham Group

    Participants who will received photobiomodulation irradiation with the transcutaneous ILIB method, with the device turned-off

    Device: Modified ILIB Sham Photobiomodulation Therapy

Interventions

  • DevicePanel Effective Photobiomodulation Therapy

    Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals. This group will receive photobiomodulation from a whole-body panel of low intensity LEDs

  • DeviceSham Panel Photobiomodulation Therapy

    Use of common red lamp to perform the sham photobiomodulation for the panel group

  • DeviceModified ILIB Sham Photobiomodulation Therapy

    ILIB Therapy device turned off for the sham ILIB therapy

  • DeviceModified ILIB Photobiomodulation Therapy

    Common laser used in ILIB mode for modified ILIB therapy

06

What researchers measure

Primary outcomes

  1. Diastolic Blood Pressure

    Diastolic blood pressure measured in millimeters of mercury (mmHg)

    Time frame: Acute effect (immediately post-intervention until 24 hours after)

Secondary outcomes

  1. Systolic Blood Pressure

    systolic blood pressure measured in millimeters of mercury (mmHg)

    Time frame: Acute effect (immediately post-intervention until 24 hours after)

  2. Mean Arterial Pressure

    mean arterial pressure measured in millimeters of mercury (mmHg)

    Time frame: Acute effect (immediately post-intervention until 24 hours after)

  3. Endothelial Function

    Endothelial function measured by flow-mediated dilation, with a brachial artery ultrasound

    Time frame: Acute effect (About 25 minutes post-intervention)

  4. Arterial Stiffness

    Arterial stiffness measured by pulse wave velocity

    Time frame: Acute effect (About 15 minutes post-intervention)

  5. Blood Nitrite

    Blood nitrite levels

    Time frame: Acute effect (1 hour post-intervention)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2025, 8 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2024
First posted
Nov 7, 2024
StartActual
May 1, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Jan 30, 2025
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678698
Lead sponsor
Universidade Federal de Sao Carlos
Collaborators
The São Paulo Research Foundation (FAPESP)
Responsible party
Lara Maria Bataglia Espósito (Physical Therapist, Master's student, Universidade Federal de Sao Carlos) — Principal investigator
First posted
Nov 7, 2024
Start date
May 1, 2024
Primary completion
Jan 30, 2025 (estimated)
Completion
Jan 30, 2025 (estimated)
Last update
Nov 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion